Predicting osteoporosis medication receipt in Veterans with a spinal cord injury: A retrospective cohort study

References

• Spinal Cord Injury Facts and Figures at a Glance. 2012; https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202012%20Feb%20Final.pdf. Accessed May 3, 2017.
   Google Scholar
• Abderhalden L, Weaver FM, Bethel M, Demirtas H, Burns S, Svircev J, et al. Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders. Osteoporos Int. 2017;28(3):925–34. doi: 10.1007/s00198-016-3841-y
   PubMed Web of Science ®Google Scholar
• Carbone LD, Chin AS, Burns SP, Svircev JN, Hoenig H, Heggeness M, et al. Mortality after lower extremity fractures in men with spinal cord injury. J Bone Miner Res. 2014;29(2):432–9. doi: 10.1002/jbmr.2050
   PubMed Web of Science ®Google Scholar
• Carbone L, et al. The association of anticonvulsant use with fractures in spinal cord injury. Am J Phys Med Rehab. 2013;24:2261–7.
   Google Scholar
• Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. vertebral efficacy with risedronate therapy (VERT) study group. JAMA. 1999;282(14):1344–52. doi: 10.1001/jama.282.14.1344
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. fracture Intervention Trial research group. Lancet. 1996;348(9041):1535–41. doi: 10.1016/S0140-6736(96)07088-2
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22. doi: 10.1056/NEJMoa067312
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81. doi: 10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• Morse LR, Giangregorio L, Battaglino RA, Holland R, Craven BC, Stolzmann KL, et al. VA-based survey of osteoporosis management in spinal cord injury. Pm r. 2009;1(3):240–4. doi: 10.1016/j.pmrj.2008.10.008
   PubMedGoogle Scholar
• Smith BM, Evans CT, Ullrich P, Burns S, Guihan M, Miskevics S, et al. Using VA data for research in persons with spinal cord injuries and disorders: lessons from SCI QUERI. J Rehabil Res Dev. 2010;47(8):679–88. doi: 10.1682/JRRD.2009.08.0117
   PubMed Web of Science ®Google Scholar
• (CDW) CDW. VA Informatics and computing infrastructure: corporate data warehouse (CDW). 2009; http://www.virec.research.va.gov/DSS-NNDEs.htm. Accessed April 2, 2018.
   Google Scholar
• Bethel M, Weaver FM, Bailey L, Miskevics S, Svircev JN, Burns SP, et al. Risk factors for osteoporotic fractures in persons with spinal cord injuries and disorders. Osteoporos Int. 2016;27(10):3011–21. doi: 10.1007/s00198-016-3627-2
   PubMed Web of Science ®Google Scholar
• Carbone LD, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, et al. The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med. 2013;36(2):91–6. doi: 10.1179/2045772312Y.0000000060
   PubMed Web of Science ®Google Scholar
• Carbone L, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig H, et al. The association of anticonvulsant use with fractures in spinal cord injury. Am J Phys Med Rehabil. 2013;92(12):1037–46. quiz 47-50. doi: 10.1097/PHM.0000000000000014
   PubMed Web of Science ®Google Scholar
• Qin W, Bauman WA, Cardozo C. Bone and muscle loss after spinal cord injury: organ interactions. Ann N Y Acad Sci. 2010;1211:66–84. doi: 10.1111/j.1749-6632.2010.05806.x
   PubMed Web of Science ®Google Scholar
• Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, et al. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord. 2014;15:112. doi: 10.1186/1471-2474-15-112
   PubMed Web of Science ®Google Scholar
• Burkard D, Beckett T, Kourtjian E, Messingschlager C, Sipahi R, Padley M, et al. Effects of bone remodeling agents following teriparatide treatment. Osteoporos Int. 2018;29(16):1351–57. doi: 10.1007/s00198-018-4434-8
   PubMedGoogle Scholar
• Qaseem A, Forciea MA, McLean RM, Denberg TD. Clinical guidelines committee of the American college of P. treatment of Low bone density or osteoporosis to prevent fractures in Men and women: a clinical practice guideline update from the American college of physicians. Ann Intern Med. 2017;166(11):818–39. doi: 10.7326/M15-1361
   PubMed Web of Science ®Google Scholar
• Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D. Osteoporosis: a review of treatment options. Pharm Ther. 2018;43(2):92–104.
   Google Scholar
• Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929–37. doi: 10.1002/jbmr.2202
   PubMed Web of Science ®Google Scholar
• Hayes BL, Curtis JR, Laster A, Saag K, Tanner SB, Liu C, et al. Osteoporosis care in the United States after declines in reimbursements for DXA. J Clin Densitom. 2010;13(4):352–60. doi: 10.1016/j.jocd.2010.08.001
   PubMed Web of Science ®Google Scholar
• Desai RJ, Mahesri M, Abdia Y, Barberio J, Tong A, Zhang D, et al. Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvetebral fractures: An instrumental variable analysis. JAMA Open. 2018;1(3):e180826. doi:10.1001/jamanetworkopen.2018.0826 doi: 10.1001/jamanetworkopen.2018.0826
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. HORIZON recurrent fracture trial. Zolendronic acid and clinical fractures and morality after hip fracture. N Engl JMed. 2007;357(18):1799–809. doi: 10.1056/NEJMoa074941
   PubMed Web of Science ®Google Scholar
• Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: An ecological analysis. J Bone Miner Res. 2015;30(12):2179–87. doi: 10.1002/jbmr.2565
   PubMed Web of Science ®Google Scholar
• Garland DE, Adkins RH, Kushwaha V, Stewart C. Risk factors for osteoporosis at the knee in the spinal cord injury population. J Spinal Cord Med. 2004;27(3):202–6. doi: 10.1080/10790268.2004.11753748
   PubMed Web of Science ®Google Scholar
• Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775–80. doi: 10.1007/s00198-016-3868-0
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000. doi: 10.1359/jbmr.2000.15.6.993
   PubMed Web of Science ®Google Scholar
• Hatch MN, Raad J, Suda K, Stroupe KT, Hon AJ, Smith BM. Evaluating the use of medicare Part D in the spinal cord injury/disorder Veteran population. Arch Phys Med Rehabil. 2018;99(6):1099–107. doi: 10.1016/j.apmr.2017.12.036
   PubMed Web of Science ®Google Scholar
• Viana R, Payne MW. Use of calcitonin in recalcitrant phantom limb pain complicated by heterotopic ossification. Pain Res Manag. 2015;20(5):229–33. doi: 10.1155/2015/782948
   PubMed Web of Science ®Google Scholar
• Yeh MW, Zhou H, Adams AL, Ituarte PH, Li N, Liu IL, et al. The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study. Ann Intern Med. 2016;164(11):715–23. doi: 10.7326/M15-1232
   PubMed Web of Science ®Google Scholar